One pill to tackle two heart risks: new combo drug enters final testing

NCT ID NCT06643130

Recruiting now Disease control Sponsor: JW Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether a new combination drug (JW0104+C2402) can safely lower both blood pressure and LDL cholesterol in people with hypertension and dyslipidemia. 162 participants will take the drug once daily for 8 weeks. The study is randomized and double-blind, meaning neither patients nor doctors know who gets which treatment, to ensure fair results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JW0104+C2402 (a combination drug taken by mouth once daily)
What this could lead to: If successful, this could offer a new once-daily pill that treats both high blood pressure and high cholesterol at the same time, simplifying treatment for patients.
What could go wrong: This is a mid-stage trial with only 162 people over 8 weeks, so results may not apply to everyone. The drug may not work better than existing options or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias hypertensive disorder inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIA HYPERTENSION

Contacts and locations

Locations

Gangdong Sacred Heart Hospital
RECRUITING

Seoul, 05355, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.